We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Escitalopram and Depression in Elderly Alzheimer's Patients

This study has been terminated.
(Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00488670
First Posted: June 20, 2007
Last Update Posted: June 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of British Columbia
  Purpose
To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Condition Intervention Phase
Depressive Disorder Drug: Escitalopram Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Change in Cornell Scale for Depression in Dementia (CSDD) from baseline. [ Time Frame: Unspecified ]

Secondary Outcome Measures:
  • Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study [ Time Frame: Unspecified ]

Estimated Enrollment: 50
Study Start Date: December 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Escitalopram
    See Detailed Description.
Detailed Description:
This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00488670


Locations
Canada, British Columbia
Mt. St. Joseph's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Kiran Rabheru, MD University of British Columbia
  More Information

Responsible Party: Dr. Kiran Rabheru, University of British Columbia
ClinicalTrials.gov Identifier: NCT00488670     History of Changes
Other Study ID Numbers: H07-00050
First Submitted: June 18, 2007
First Posted: June 20, 2007
Last Update Posted: June 6, 2011
Last Verified: June 2011

Keywords provided by University of British Columbia:
Alzheimer's disease
elderly
open-label
escitalopram

Additional relevant MeSH terms:
Alzheimer Disease
Depressive Disorder
Depression
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Mood Disorders
Behavioral Symptoms
Citalopram
Dexetimide
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents


To Top